Suboxone | Addiction Professional Magazine Skip to content Skip to navigation

Suboxone

FDA approves once-monthly injectable buprenorphine product

December 1, 2017  |  Tom Valentino, Senior Editor
article
The FDA has approved a once-monthly injectable form of buprenorphine for the treatment of opioid use disorder, but clinicians are lukewarm on its use.

Cost analysis backs immediate access to agonist drugs for opioid dependence

November 29, 2017  |  Gary A. Enos, Editor
article
A cost-effectiveness analysis using California data makes a strong case for significant public investment in methadone and buprenorphine treatment.

Drug studies' results make case for access to all opioid dependence medications

November 16, 2017  |  Gary A. Enos, Editor
article
Recent efficacy and safety studies found comparable and encouraging results for buprenorphine and injectable naltrexone in the treatment of opioid dependence.

FDA clears electrical device to combat opioid withdrawal

November 15, 2017  |  Gary A. Enos, Editor
news
The Food and Drug Administration (FDA) today announced that an electrical stimulation device attached to the ear can be marketed for the treatment of symptoms of opioid withdrawal.

Hospital boosts opioid patients' rapid access to medication

November 14, 2017  |  Gary A. Enos, Editor
article
The experience of Boston Medical Center bolsters evidence that hospitalized patients with opioid use disorders can be successfully initiated on medication before discharge.

Injectable buprenorphine moves closer to approval

November 2, 2017  |  Gary A. Enos, Editor
news
It appears likely that the first monthly injectable formulation of buprenorphine to treat opioid dependence will receive federal approval by the end of this month.

Fact sheet on opioid treatments targets justice officials

October 27, 2017  |  Gary A. Enos, Editor
article
The American Association for the Treatment of Opioid Dependence (AATOD) seeks to separate ideology from evidence in discussing the importance of medication treatments in the justice system.

Troncale urges rejection of extreme positions on role of medication treatment

October 3, 2017  |  Gary A. Enos, Editor
article
In his "If I were king" talk at the Moments of Change conference, the medical director at Retreat Premier Addiction Treatment Centers advocated a balanced and comprehensive approach to combating the opioid crisis.

FDA issues guidance on MAT drugs

September 25, 2017  |  Tom Valentino, Senior Editor
article
The FDA is alerting providers and patients of the dangers of combining MAT drugs with benzodiazepines, a move that follows a recent change in labeling requirements for buprenorphine to indicate patients may require indefinite treatment.

Opioid treatment programs growing, and expanding into other medications

August 23, 2017  |  Gary A. Enos, Editor
news
Today's opioid treatment programs (OTPs) are increasingly likely to be offering buprenorphine and injectable naltrexone treatment in addition to methadone.

NCAD: Doctor attacks misconceptions about opioid addiction medications

August 20, 2017  |  Gary A. Enos, Editor
article
The owner of Addiction Recovery Resources in Louisiana discussed why it makes sense to integrate 12-Step and medication approaches to opioid addiction treatment.

Stigma apparent in physician replies to survey on buprenorphine prescribing

August 8, 2017  |  Gary A. Enos, Editor
article
A 2016 physician survey on the prescribing of buprenorphine does indicate that counselors and other specialty providers could help physicians overcome reluctance to prescribe the opioid dependence treatment.

Pages

Subscribe to Suboxone